Trial Profile
Study evaluating the Cardiovascular safety of Febuxostat compared to Allopurinol in patients with Gout or Hyperuricemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2018
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary) ; Allopurinol
- Indications Hyperuricaemia
- Focus Adverse reactions
- 21 Sep 2018 New trial record
- 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management